Chronic Kidney Disease Pharmacology

Metformin is entirely renally excreted by tubular secretion and accumulates in chronic kidney disease in direct proportion to the decline in glomerular filtration rate. Accumulation raises plasma lactate by inhibiting hepatic lactate clearance, creating the substrate for metformin-associated lactic acidosis — a rare but potentially fatal complication. Metformin is generally held when estimated glomerular filtration rate falls below 30 milliliters per minute per 1.73 square meters, and many guidelines recommend dose reduction and increased monitoring between 30 and 45 milliliters per minute. It should be withheld before procedures using iodinated contrast media and resumed only after confirming stable renal function.

Direct oral anticoagulants vary substantially in their renal elimination fraction, which determines the severity of dose accumulation in chronic kidney disease. Dabigatran is 80% renally eliminated and is contraindicated when estimated glomerular filtration rate falls below 30 milliliters per minute — the highest renal risk of the class. Apixaban has the lowest renal elimination fraction (approximately 27%) and is generally the preferred direct oral anticoagulant in advanced chronic kidney disease. Rivaroxaban and edoxaban fall between these extremes and require dose adjustment or avoidance as glomerular filtration rate declines.

Some drugs are safe at their usual dose in chronic kidney disease but accumulate dangerous active metabolites as renal clearance falls. Morphine is metabolized to morphine-6-glucuronide, an active opioid metabolite with potent respiratory depressant effects that accumulates in renal impairment even when morphine itself is dosed conservatively. Hydromorphone, oxycodone, and codeine carry similar risks through their respective active metabolites. Meperidine accumulates normeperidine, a pro-convulsant metabolite, and is avoided in chronic kidney disease entirely. Recognizing active metabolite accumulation as a distinct pharmacokinetic hazard — separate from accumulation of the parent drug — is essential to safe prescribing in patients with chronic kidney disease.

In chronic kidney disease, reduced nephron mass causes surviving nephrons to hyperfiltrate, increasing sodium reabsorption in the proximal convoluted tubule and reducing sodium delivery to the macula densa. The macula densa interprets this low sodium signal as reduced glomerular filtration and dilates the afferent arteriole to increase blood flow — but this compensatory response raises intraglomerular pressure and accelerates nephron loss. Sodium-glucose cotransporter 2 inhibitors block glucose-coupled sodium reabsorption in the proximal tubule, restoring sodium delivery to the macula densa, triggering afferent arteriolar constriction via tubuloglomerular feedback, and reducing intraglomerular pressure. This mechanism operates regardless of whether the patient has diabetes.

The CREDENCE trial randomized patients with type 2 diabetes and chronic kidney disease to canagliflozin and demonstrated a 30% relative risk reduction in the primary composite of end-stage kidney disease, doubling of serum creatinine, and renal or cardiovascular death. The DAPA-CKD trial extended this to patients without diabetes, with dapagliflozin reducing the composite of sustained decline in estimated glomerular filtration rate, end-stage kidney disease, and cardiovascular or renal death by 39% across diabetic and non-diabetic chronic kidney disease patients. These trials established sodium-glucose cotransporter 2 inhibitors as a new standard of care in chronic kidney disease management.

Genital mycotic infections are the most common adverse effect, occurring in 5 to 10% of patients; they are manageable and rarely require drug discontinuation. Euglycemic diabetic ketoacidosis can occur — serum glucose may be near-normal while ketone production is elevated — requiring clinical suspicion in patients presenting with symptoms of ketoacidosis regardless of glucose level. Fournier's gangrene, a rare necrotizing fasciitis of the perineum, carries a black box warning for the class. The glycosuric efficacy of sodium-glucose cotransporter 2 inhibitors diminishes as glomerular filtration rate declines and filtered glucose load falls, but the renoprotective effect via tubuloglomerular feedback persists at lower glomerular filtration rates than the glucose-lowering effect.

Under normal oxygen conditions, prolyl hydroxylase domain enzymes hydroxylate hypoxia-inducible factor 1-alpha, targeting it for proteasomal degradation. When oxygen tension falls — as in high altitude or anemia — prolyl hydroxylase domain enzyme activity decreases, hypoxia-inducible factor 1-alpha accumulates, and it transcriptionally upregulates erythropoietin production, iron transport genes, and other adaptive responses. Prolyl hydroxylase domain inhibitors pharmacologically block these enzymes, mimicking hypoxia and stabilizing hypoxia-inducible factor 1-alpha regardless of ambient oxygen tension, thereby stimulating endogenous erythropoietin production.

Roxadustat was the first prolyl hydroxylase domain inhibitor approved for chronic kidney disease anemia and is available in Europe, Japan, and China. Daprodustat received approval in the United States and Japan. Phase 3 trials demonstrated that both agents produce hemoglobin increases comparable to erythropoiesis-stimulating agents in both dialysis-dependent and non-dialysis chronic kidney disease patients. A key pharmacological advantage is their oral administration — erythropoiesis-stimulating agents require injection. Cardiovascular safety data from phase 3 trials are under ongoing scrutiny, and these agents are currently positioned as alternatives for patients who do not respond adequately to or cannot receive erythropoiesis-stimulating agents.